Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK emergency contraception access

This article was originally published in The Tan Sheet

Executive Summary

Women should be able to obtain emergency contraceptive pills in advance of actually needing to use them, the UK's Family Planning Association urges as part of its Contraceptive Awareness Week 2004. More than 75% of the 100,000 women who call FPA's helpline each year would like to have "access through the bathroom cabinet," but nearly half of family planning clinics questioned do not provide this service, the organization says. FPA will campaign for increased access to EC through distribution of posters and leaflets to selected health professionals and student unions during Awareness Week. Emergency contraceptives were approved for pharmacy status in the UK in December 2000 (1"The Tan Sheet" Dec. 18, 2000, p. 3)...

You may also be interested in...

Plan B Emergency Contraceptive Switch NDA Planned

Women's Capital Corporation will file an NDA next year to switch its Plan B emergency contraceptive to OTC status, the company said Dec. 13.

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts